Induction of class II MHC antigen expression on the murine placenta by 5-azacytidine correlates with fetal abortion.
During the gestational cycle the placental tissue does not express class II MHC antigens and whether this phenomenon is important to fetal survival has not yet been evoked. It has been reported that class II antigen expression precedes renal and cardiac graft rejection, which may also be the case in fetal abortion. In a recent report we showed that placental cells can be induced to express class II antigens in vitro and that these cells undergo different regulatory mechanisms depending on their anatomical position in the placenta. Thus, spongiotrophoblast-derived cells express these antigens after interferon-gamma treatment, whereas labyrinthine trophoblast-derived cells are induced by 5-azacytidine. In the present study we examined the effect of 5-azacytidine on class II antigen expression in the placenta and fetal abortion in vivo. We report that 5-azacytidine, when given to pregnant females before the ectoplacental cone formation, dramatically increases fetal loss, which correlates with class II antigen expression in the labyrinthine trophoblast zone. No site effects of 5-azacytidine on placental cell proliferation, splenic T and B cell responses, or reproductive capability of treated females were observed. However, after treatment with 5-azacytidine placental cells can stimulate maternal spleen cells to proliferate in a mixed cell reaction, whereas untreated controls cannot. Furthermore, the abortive effect of 5-azacytidine can be rescued in allogeneic pregnancy by anti-paternal class II monoclonal antibody injection into the animals during the 5-azacytidine treatment. These results suggest that the maintenance of the class II antigen-negative expression on the placenta is indeed necessary to avoid maternal immune attack and ensure fetal survival.
Institute of Molecular Biology and Biotechnology, Crete, Greece.
I
I
Athanassakis-Vassiliadis
V K
VK
Galanopoulos
M
M
Grigoriou
J
J
Papamatheakis
D000818:Animals; D001374:Azacitidine / Q000494:pharmacology*; D015152:Blotting, Northern; D005260:Female; D005313:Fetal Death / Q000139:chemically induced / Q000276:immunology; D015870:Gene Expression / Q000187:drug effects; D005865:Gestational Age; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D007124:Immunoenzyme Techniques; D008213:Lymphocyte Activation / Q000187:drug effects; D008285:Major Histocompatibility Complex; D008745:Methylation; D051379:Mice; D008815:Mice, Inbred Strains; D010920:Placenta / Q000276:immunology*; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects* / Q000276:immunology; D013154:Spleen / Q000276:immunology; D014327:Trophoblasts / Q000276:immunology
D000949:Histocompatibility Antigens Class II; D001374:Azacitidine